Journal Mobile Options
Table of Contents
Vol. 43, No. 3, 2001
Issue release date: March 2001

mRNA Expression of Serotonin Receptors of Type 2C and 5A in Human Resting Lymphocytes

Marazziti D. · Ori M. · Nardini M. · Rossi A. · Nardi I. · Cassano G.B.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

We investigated the presence of mRNA for serotonin receptors of type 2C (5-HT2C) in resting lymphocytes by means of RT-PCR and Southern blotting analyses, given their possible role in the pathophysiology of anxiety and eating disorders. At the same time, we explored also the presence of the specific mRNA for 5-HT5A receptors, a novel subtype for which still no functional data exist. Healthy subjects and patients with obsessive-compulsive or bipolar disorders were included in the study. The results showed the presence of the specific mRNAs for both 5-HT2C and 5-HT5A receptors in resting lymphocytes of the three groups of subjects. An additional band was also observed after the amplification of the 5-HT5A cDNA in each sample. These findings, while revealing the presence of 5-HT2C and 5-HT5A receptor mRNAs in an easily available tissue, can be considered preliminary for future quantitative analyses in patients with different psychiatric conditions.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Boess FG, Martin IL: Molecular biology of 5-HT receptors. Neuropharmacology 1994;33:275–317.
  2. Hoyer D, Martin G: 5-HT receptor classification and nomenclature: Towards a harmonization with the human genome. Neuropharmacology 1997;36:419–428.
  3. Charney DS, Woods SW, Goodman WK, Heninger GR: Serotonin function in anxiety: Effects of the serotonin agonist m-CCP in panic disorder patients and healthy subjects. Psychopharmacology (Berl) 1987;92:14–24.
  4. Pigott TA, Zohar J, Hill JL, Bernstein SE, Grover GN, Zohar-Kadouch R, Murphy DL: Metergoline blocks the behavioral and neuroendocrine effects of orally administered m-chlorophenylpiperazine in patients with obsessive-compulsive disorder. Biol Psychiatry 1991;29:418–426.
  5. Germin M, Goddard AW, Sholomskas DE, Woods SW, Charney DS, Heninger GR: Response to meta-chlorophenylpiperazine in panic disorder patients and healthy subjects: Influence of reduction in intravenous dosage. Psychiatry Res 1994;54:125–133.

    External Resources

  6. Tecott LH, Sun LM, Akana SF, Strack AM, Lowenstein DH, Dallman MF, Julius D: Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature 1995;374:542–546.
  7. Pasqualetti M, Ori M, Nardi I, Castagna M, Cassano GB, Marazziti D: Distribution of the 5-HT5A serotonin receptor mRNA in the human brain. Brain Res Mol Brain Res 1998;56:1–8.

    External Resources

  8. American Psychiatric Association, Committee on Nomenclature and Statistics: Diagnostic and Statistical Manual for Mental Disorders, ed 4. Washington, American Psychiatric Press, 1994.
  9. Goodman WK, Price LH, Rasmussen SA: The Yale Brown Obsessive-Compulsive Scale I: Development, use and reliability. Arch Gen Psychiatry 1986;46:1006–1011.
  10. Marazziti D, Rossi A, Giannacchini G, Baroni S, Lucacchini A, Cassano GB: Presence and characterization of the serotonin transporter in human resting lymphocytes. Neuropsychopharmacology 1998;19:154–159.
  11. Saltzman AG, Morse B, Whitman MM, Ivanshchenko YM, Felder S: Cloning of the human serotonin 5-HT2A and 5-HT1C receptor subtypes. Biochem Biophys Res Commun 1991;181:1469–1478.

    External Resources

  12. Rees S, den Daas I, Foord S, Goodson S, Bull D, Kilpatrick G, Lee M: Cloning and characterization of the human 5-HT5A serotonin receptor. FEBS Lett 1994;355:242–246.
  13. Pazos A, Hoyer D, Palacios JM: The binding of serotonergic ligands to the porcine choroid plexus: Characterization of a new type of serotonin recognition site. Eur J Pharmacol 1985;106:539–546.
  14. Pazos A, Probst A, Palacios JM: Serotonin receptors in the human brain. III. Autoradiographic mapping of serotonin-1 receptors. Neuroscience 1987;21:97–122.
  15. Hoyer D, Pazos A, Probst A, Palacios JM: Serotonin receptors in the human brain II. Characterization and autoradiographic localization of 5-HT1C and 5-HT2 recognition sites. Brain Res 1986;376:97–107.
  16. Pasqualetti M, Ori M, Castagna M, Marazziti D, Cassano GB, Nardi I: Distribution and cellular localization of the serotonin type 2C receptor messenger RNA in human brain. Neuroscience 1999;92:601–611.
  17. Zohar J, Mueller EA, Insel TR, Zohar-Kadouch RC, Murphy DL: Serotonergic responsivity in obsessive-compulsive disorder. Arch Gen Psychiatry 1987;44:946–951.
  18. Hollander E, Fay M, Cohen B, Campeas R, Gorman JM, Liebowitz MR: Serotonergic and noradrenergic sensitivity in obsessive-compulsive disorder: Behavioral findings. Am J Psychiatry 1988;145:1015–1017.
  19. Marazziti D, Nardi I, Cassano GB: Autism, serotonin and cerebellum: Might there be a connection? CNS Spectrums 1998;3:80–82.
  20. Grailhe R, Waeber C, Dulawa SC, Hornung JP, Zhuang X, Brunner D, Geyer MA, Hen R: Increased exploratory activity and altered response to LSD in mice lacking the 5-HT5A receptor. Neuron 1999;22:581–591.

    External Resources

  21. Altemus M, Murphy DL, Greenberg B, Lesch KP: Intact coding region of the serotonin transporter gene in obsessive-compulsive disorder. Am J Med Genet 1996;67:409–411.


Pay-per-View Options
Direct payment This item at the regular price: USD 33.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00